David Shannon C, Lau Josyane, Singleton Eve V, Babb Rachelle, Davies Justin, Hirst Timothy R, McColl Shaun R, Paton James C, Alsharifi Mohammed
Research Centre for Infectious Diseases, and Department of Molecular and Cellular Biology, School of Biological Sciences, University of Adelaide, Adelaide, SA 5005, Australia.
Australian Nuclear Science and Technology Organisation, Lucas Heights, NSW 2234, Australia.
Vaccine. 2017 Feb 15;35(7):1071-1079. doi: 10.1016/j.vaccine.2016.12.044. Epub 2017 Jan 18.
Gamma-irradiation, particularly an irradiation dose of 50kGy, has been utilised widely to sterilise highly pathogenic agents such as Ebola, Marburg Virus, and Avian Influenza H5N1. We have reported previously that intranasal vaccination with a gamma-irradiated Influenza A virus vaccine (γ-Flu) results in cross-protective immunity. Considering the possible inclusion of highly pathogenic Influenza strains in future clinical development of γ-Flu, an irradiation dose of 50kGy may be used to enhance vaccine safety beyond the internationally accepted Sterility Assurance Level (SAL). Thus, we investigated the effect of irradiation conditions, including high irradiation doses, on the immunogenicity of γ-Flu. Our data confirm that irradiation at low temperatures (using dry-ice) is associated with reduced damage to viral structure compared with irradiation at room temperature. In addition, a single intranasal vaccination with γ-Flu irradiated on dry-ice with either 25 or 50kGy induced seroconversion and provided complete protection against lethal Influenza A challenge. Considering that low temperature is expected to reduce the protein damage associated with exposure to high irradiation doses, we titrated the vaccine dose to verify the efficacy of 50kGy γ-Flu. Our data demonstrate that exposure to 50kGy on dry-ice is associated with limited effect on vaccine immunogenicity, apparent only when using very low vaccine doses. Overall, our data highlight the immunogenicity of influenza virus irradiated at 50kGy for induction of high titre antibody and cytotoxic T-cell responses. This suggests these conditions are suitable for development of γ-Flu vaccines based on highly pathogenic Influenza A viruses.
伽马射线辐照,尤其是50千戈瑞的辐照剂量,已被广泛用于对埃博拉病毒、马尔堡病毒和禽流感H5N1等高致病性病原体进行消毒。我们之前曾报道,用伽马射线辐照的甲型流感病毒疫苗(γ-Flu)进行鼻内接种可产生交叉保护性免疫。考虑到γ-Flu未来临床开发中可能会纳入高致病性流感毒株,50千戈瑞的辐照剂量可用于提高疫苗安全性,使其超过国际认可的无菌保证水平(SAL)。因此,我们研究了包括高辐照剂量在内的辐照条件对γ-Flu免疫原性的影响。我们的数据证实,与室温辐照相比,低温(使用干冰)辐照对病毒结构的损伤较小。此外,用25或50千戈瑞在干冰上辐照的γ-Flu进行单次鼻内接种可诱导血清转化,并提供针对致死性甲型流感攻击的完全保护。考虑到低温有望减少与高辐照剂量暴露相关的蛋白质损伤,我们对疫苗剂量进行了滴定,以验证50千戈瑞γ-Flu的疗效。我们的数据表明,在干冰上暴露于50千戈瑞对疫苗免疫原性的影响有限,仅在使用非常低的疫苗剂量时才明显。总体而言,我们的数据突出了50千戈瑞辐照的流感病毒诱导高滴度抗体和细胞毒性T细胞反应的免疫原性。这表明这些条件适用于基于高致病性甲型流感病毒的γ-Flu疫苗的开发。